Correlation between CYP2C19 gene polymorphism and voriconazole valley concentration and adverse drug reactions

doi:10.3877/cma.j.issn.2095-5820.2025.02.005

Abstract

Abstract:

Objective

To investigate the association between CYP2C19 gene polymorphism and voriconazole valley concentration and adverse drug reactions, so as to provide evidence for clinical dose adjustment.

Methods

327 patients treated with voriconazole from January 2021 to July 2023 who were simultaneously monitored with voriconazole concentration and detected with CYP2C19 gene polymorphism at the First Affiliated Hospital of Guangzhou Medical University were retrospectively analyzed, recorded their basic information, CYP2C19 genotype, dosage, duration of administration, blood concentration and abnormal liver function. Analysis of the relationship between CYP2C19 gene polymorphism and voriconazole steady-state plasma concentration and liver function abnormalities.

Results

CYP2C19 normal metabolizer and intermediate metabolizer accounted for 43.12%, and poor metabolizer accounted for 13.76%. There are statistical differences in serum voriconazole concentration among different CYP2C19 genotype carriers (P＜0.05). However, no statistically significant association was found between CYP2C19 gene polymorphisms and adverse drug reactions(P＞0.05).

Conclusion

CYP2C19 gene polymorphism affects voriconazole metabolism in vivo, but has no statistical correlation with adverse reactions after voriconazole use.

Key words: CYP2C19 gene polymorphism, voriconazole, adverse drug reaction

Junkai Ye, Hui Xie, Bo Xiang, Ya Li. Correlation between CYP2C19 gene polymorphism and voriconazole valley concentration and adverse drug reactions[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2025, 13(02): 91-96.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2025.02.005

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2025/V13/I02/91

Figures/Tables 10

References 23

1	陈恳, 张相林, 克晓燕, 等. 《伏立康唑个体化用药指南》解读[J].临床药物治疗杂志, 2019, 17 (3): 47-52, 78.
2	陈婷婷, 张清泉, 林志强. 住院患者中伏立康唑相关药物相互作用医嘱的发生情况分析[J]. 药物不良反应杂志, 2024, 26(8): 454-459.
3	林志强, 张清泉, 陈婷婷. 伏立康唑的治疗药物监测：国内外相关指南概览[J]. 药物不良反应杂志, 2020, 22(7): 409-415.
4	杨森, 吴上志, 黄展航, 等. CYP2C19基因多态性对肺部侵袭性真菌感染患儿伏立康唑血药谷浓度的影响及其潜在机制[J]. 解放军医学杂志, 2023, 48(10): 1174-1179.
5	MIAO Q, TANG J T, VAN GELDER T, et al. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese han patients with invasive fungal infections[J]. Medicine (Baltimore),2019, 98(3): e14137.
6	ZHANG Y, HOU K, LIU F, et al. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis[J]. Mycoses, 2021, 64(8): 860-873.
7	彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J].药学实践杂志, 2015(6): 508-512.
8	李祥, 苏铎华, 邢贞建, 等. CYP2C19基因多态性对预测侵袭性肺曲霉病患者伏立康唑相关不良反应的作用[J]. 实用医学杂志, 2021,37(9): 1168-1171.
9	OWUSU OBENG A, EGELUND E F, ALSULTAN A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole:Are we ready for clinical implementation of pharmacogenomics?[J].Pharmacotherapy, 2014, 34(7): 703-718.
10	陈金成, 许秋霞, 庄奕筠, 等. 基于血药浓度监测和CYP2C19基因检测的伏立康唑疗效及药物不良反应相关性临床研究[J]. 中国临床药理学杂志, 2023, 39 (13): 1827-1830.
11	KARLSSON M O, LUTSAR I, MILLIGAN P A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies[J]. Antimicrobial agents and chemotherapy,2009, 53(3): 935-944.
12	FRIBERG L E, RAVVA P, KARLSSON M O, et al. Integrated population pharmacokinetic analysis of voriconazole in children,adolescents, and adults[J]. Antimicrobial agents and chemotherapy,2012, 56(6): 3032-3042.
13	HOPE W W. Population pharmacokinetics of voriconazole in adults[J].Antimicrobial agents and chemotherapy, 2012, 56(1): 526-531.
14	WANG T, ZHU H, SUN J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections[J]. International journal of antimicrobial agents, 2014, 44(5): 436-442.
15	CHEN K, ZHANG X, KE X, et al. Individualized medication of voriconazole: A practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J].Therapeutic drug monitoring, 2018, 40(6): 663-674.
16	靳庆敏, 葛茂宏. CYP2C19基因多态性对抗抑郁剂代谢影响的研究进展[J]. 精神医学杂志, 2017, 30(04): 297-299.
17	BERNAL-MARTÍNEZ L, ALCAZAR FUOLI L, MIGUEL-REVILLA B, et al. High-resolution melting assay for genotyping variants of the CYP2C19 enzyme and predicting voriconazole effectiveness[J].Antimicrobial agents and chemotherapy, 2019, 63(6): e02399-18.
18	CHEN X, XIAO Y, LI H, et al. Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children[J]. Translational pediatrics, 2022, 11(8): 1311-1322.
19	刘雨, 高杏, 薛婷, 等. CYP2C19～*3位点不同基因型重症侵袭性真菌感染患者接受伏立康唑治疗时的血药浓度及疗效对比观察[J].山东医药, 2020, 60 (33): 35-38.
20	李艺, 张蕾, 冯晓俊, 等. CYP2C19基因多态性对伏立康唑不良反应发生率的影响[J]. 中国医药导报, 2019, 16(6): 8-11.
21	TANAKA R, FUJIOKA T, SUZUKI Y, et al. A prospective study on the usefulness of initial voriconazole dose adjustment based on CYP2C19 gene polymorphism analysis[J]. Chemotherapy, 2020, 65(3-4): 59-64.
22	WANG T, YAN M, TANG D, et al. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study[J]. International journal of infectious diseases: Official publication of the International Society for Infectious Diseases, 2018, 72: 49-54.
23	申川, 李子月, 王玮, 等. 基于CYP2C19基因多态性检测与伏立康唑血药浓度监测治疗成功的肝衰竭合并侵袭性肺曲霉病患者1例[J].中国临床案例成果数据库, 2022, 04(1): E01987-E01987.

参数	数量/例	比例/%
性别
男	260	79.51
女	67	20.49
吸烟史	168	51.38
饮酒史	38	11.62
CYP2C19 基因多态性
NM	141	43.12
IM	141	43.12
PM	45	13.76
初次使用剂量/（mg/d）
200~399	21	6.42
400	216	66.06
401~600	80	24.46
601~1000	10	3.06

参数	数量/例	比例/%
性别
男	260	79.51
女	67	20.49
吸烟史	168	51.38
饮酒史	38	11.62
CYP2C19 基因多态性
NM	141	43.12
IM	141	43.12
PM	45	13.76
初次使用剂量/（mg/d）
200~399	21	6.42
400	216	66.06
401~600	80	24.46
601~1000	10	3.06

初次使用剂量/（mg/d）	产生不良反应血药谷浓度/（mg/L）	F 值	P 值
200~399	1.68±0.93	1.649	0.186
400	3.45±2.60
401~600	2.65±1.81
601~1000	4.35±2.81

初次使用剂量/（mg/d）	产生不良反应血药谷浓度/（mg/L）	F 值	P 值
200~399	1.68±0.93	1.649	0.186
400	3.45±2.60
401~600	2.65±1.81
601~1000	4.35±2.81

检测结果	初次检测（n=327）	再次检测（n=71）
达到目标治疗浓度	235（71.87）	40（56.34）
未达到目标治疗浓度	92（28.13）	31（43.66）

Please choose a citation manager

Content to export